特朗普政府周二宣布为美国食品药品监督管理局(FDA)的四个高级职位任命新人选1。这些任命涵盖了该机构的关键领域，在数月的高管流失和政策争议后为该机构提供了稳定性1。
Michael Davis被任命为FDA药物评估和研究中心主任，将负责处方药和非处方药的安全性和有效性1。Karim Mikhail获任FDA疫苗中心常任主任，接替3月辞职的Vinay Prasad1。Bret Koplow成为烟草制品中心主任1，Jared Seehafer将担任新创设的人工智能和技术监管职位1。这些任命所涉及的领域在特朗普政府下都经历了重大政策转变1。
前任FDA专员Marty Makary因处理新冠疫苗政策方式在5月辞职1。特朗普和卫生部长Robert F. Kennedy均强调了加快迷幻药审查速度的必要性1。
The Trump administration on Tuesday announced new appointments to four high-ranking positions at the U.S. Food and Drug Administration, bringing leadership to critical divisions overseeing pharmaceuticals, vaccines, and tobacco products.1 The moves come after the agency experienced months of controversy and executive departures, offering institutional stability to an organization undergoing significant policy shifts under the current administration.1
Michael Davis has been named director of the FDA's Center for Drug Evaluation and Research, where he will oversee the safety and effectiveness of prescription and over-the-counter medications.1 Karim Mikhail will serve as permanent director of the agency's vaccine center, replacing Vinay Prasad, who departed in March.1 Bret Koplow has been appointed to lead the Center for Tobacco Products.1 Additionally, Jared Seehafer will fill a newly created position focused on artificial intelligence and regulatory technology.1
These appointments occur as the FDA navigates policy priorities central to the Trump administration's agenda, including accelerated review processes for psychedelic drugs, which both President Trump and Health and Human Services Secretary Robert F. Kennedy have emphasized as necessary.1 The replacements address vacancies created in part by the May resignation of former FDA Commissioner Marty Makary, who faced criticism over his handling of COVID-19 vaccine policy.1
评论
还没有评论，欢迎留下第一条。